Factors V leiden and II 20210A in patients with symptomatic pulmonary embolism and deep vein thrombosis.

[1]  J. Nilsson,et al.  Location and Extent of Deep Vein Thrombosis in Patients with and without FV:R 506Q Mutation , 2000, Thrombosis and Haemostasis.

[2]  A. Tosetto,et al.  The VITA Project: Prothrombin G20210A Mutation and Venous Thromboembolism in the General Population , 1999, Thrombosis and Haemostasis.

[3]  Samuel Z Goldhaber,et al.  Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER) , 1999, The Lancet.

[4]  V. Nicaud,et al.  Venous Thromboembolic Disease and the Prothrombin, Methylene Tetrahydrofolate Reductase and Factor V Genes , 1999, Thrombosis and Haemostasis.

[5]  M. Prins,et al.  Is the Prevalence of the Factor V Leiden Mutation in Patients with Pulmonary Embolism and Deep Vein Thrombosis Really Different? , 1999, Thrombosis and Haemostasis.

[6]  E. Taioli,et al.  The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels. , 1999, Thrombosis research.

[7]  J. Fontcuberta,et al.  The Prothrombin 20210A Allele Is the Most Prevalent Genetic Risk Factor for Venous Thromboembolism in the Spanish Population , 1998, Thrombosis and Haemostasis.

[8]  S. T. Dunn,et al.  Evaluation of role of factor V Leiden mutation in fatal pulmonary thromboembolism. , 1998, Thrombosis research.

[9]  P. Reitsma,et al.  Factor V Leiden and Fatal Pulmonary Embolism , 1998, Thrombosis and Haemostasis.

[10]  D. Knook,et al.  The Risk of Mortality and the Factor V Leiden Mutation in a Population-based Cohort , 1998, Thrombosis and Haemostasis.

[11]  B. Mercier,et al.  Factor V Leiden prevalence in venous thromboembolism patients. , 1997, Chest.

[12]  E. Minar,et al.  The Risk of Recurrent Venous Thromboembolism in Patients with and without Factor V Leiden , 1997, Thrombosis and Haemostasis.

[13]  J. Vandenbroucke,et al.  Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). , 1997, Blood.

[14]  P. Mannucci,et al.  Low Prevalence of Factor V:Q506 in 41 Patients with Isolated Pulmonary Embolism , 1997, Thrombosis and Haemostasis.

[15]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.

[16]  P. Reitsma,et al.  Risk Factor Profiles in Patients with Different Clinical Manifestations of Venous Thromboembolism: A Focus on the Factor V Leiden Mutation , 1996, Thrombosis and Haemostasis.

[17]  P. Simioni,et al.  An Antifibrinolytic Mechanism Describing the Prothrombotic Effect Associated with Factor VLeiden* , 1996, The Journal of Biological Chemistry.

[18]  D. Mari,et al.  Mutant factor V (Arg506Gln) in healthy centenarians , 1996, The Lancet.

[19]  P. Casey,et al.  Arachidonate and Related Unsaturated Fatty Acids Selectively Inactivate the Guanine Nucleotide-binding Regulatory Protein, G(*) , 1996, The Journal of Biological Chemistry.

[20]  M. Aiach,et al.  A rapid screening method for the factor V Arg506→Gln mutation , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[21]  P. Ridker,et al.  Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. , 1995, The New England journal of medicine.

[22]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[23]  B. Dahlbäck,et al.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[24]  G. Sutton,et al.  Comparison of Streptokinase and Heparin in Treatment of Isolated Acute Massive Pulmonary Embolism* , 1971, British heart journal.